ensysce biosciences, san diego, ca, is an integrated drug delivery company for both small and large molecules. to overcome the major problem of non-medical use of opioid products, ensysce is using its prodrug technology to improve abuse deterrent properties. the tap bio-md™ abuse deterrent and mpar™ overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route. this abuse is the fastest growing drug problem in the u.s. and it leads to billions in healthcare costs annually. for additional information about ensysce biosciences please visit www.ensysce.com.
Company profile
Ticker
ENSC
Exchange
Website
CEO
Daniel B. Silvers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Leisure Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Covistat, Inc. • EBI OpCo, Inc. • EBI Operating, Inc. ...
ENSC stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
8 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Mar 24
S-1/A
IPO registration (amended)
26 Mar 24
8-K
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
15 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
D
Exempt offering of security
20 Feb 24
424B3
Prospectus supplement
15 Feb 24
8-K
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
14 Feb 24
424B3
Prospectus supplement
14 Feb 24
S-1
IPO registration
16 Jan 24
Transcripts
Latest ownership filings
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13D/A
GOWER BOB G
18 Jul 23
4
BOB G GOWER
6 Mar 23
4
BOB G GOWER
2 Mar 23
SC 13G/A
HG Vora Capital Management, LLC
14 Feb 23
SC 13G/A
CVI Investments, Inc.
14 Feb 23
SC 13G
Lincoln Park Capital Fund, LLC
7 Feb 23
4
BOB G GOWER
1 Feb 23
SC 13G
CVI Investments, Inc.
16 Dec 22
SC 13D/A
Silvers Daniel B.
7 Jul 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.46 mm | 1.46 mm | 1.46 mm | 1.46 mm | 1.46 mm | 1.46 mm |
Cash burn (monthly) | 788.37 k | 253.23 k | 902.44 k | 1.15 mm | 754.22 k | 1.02 mm |
Cash used (since last report) | 5.23 mm | 1.68 mm | 5.99 mm | 7.61 mm | 5.01 mm | 6.79 mm |
Cash remaining | -3.77 mm | -216.84 k | -4.53 mm | -6.15 mm | -3.54 mm | -5.33 mm |
Runway (months of cash) | -4.8 | -0.9 | -5.0 | -5.4 | -4.7 | -5.2 |
Institutional ownership, Q2 2023
95.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 4 |
Closed positions | 5 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 712.73 mm |
Total shares | 6.99 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Silvers Daniel B. | 2.88 mm | $2.50 mm |
Hydra LAC | 1.87 mm | $27.07 mm |
Lincoln Park Capital Fund | 1.50 mm | $1.17 mm |
CVI Investments | 336.87 k | $0.00 |
Sabby Management | 322.30 k | $580.14 mm |
Anson Funds Management | 36.26 k | $65.27 mm |
Gsa Capital Partners | 17.55 k | $32.00 k |
Vanguard | 15.42 k | $27.75 mm |
Tower Research Capital | 3.90 k | $7.02 mm |
BLK Blackrock | 975.00 | $1.76 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Mar 23 | Bob G Gower | Common Stock | Buy | Acquire P | No | No | 0.4883 | 90,287 | 44.09 k | 1,222,682 |
1 Mar 23 | Bob G Gower | Common Stock | Buy | Acquire P | No | No | 0.4777 | 270,000 | 128.98 k | 1,132,395 |
28 Feb 23 | Bob G Gower | Common Stock | Buy | Acquire P | No | No | 0.4883 | 109,300 | 53.37 k | 862,395 |
9 Dec 22 | Bob G Gower | Buy | Acquire P | No | No | 1.4 | 357,143 | 500.00 k | 753,095 | |
9 Dec 22 | Bob G Gower | Common Stock | Grant | Acquire A | No | No | 1.4 | 714,286 | 1.00 mm | 716,365 |
News
Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate
15 Mar 24
Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)
27 Feb 24
Ensysce Biosciences Receives FDA Guidance For PF614-MPAR Program
21 Feb 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
13 Feb 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
31 Jan 24
Press releases
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
9 Apr 24
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
15 Mar 24
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
21 Feb 24
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
15 Feb 24
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
13 Feb 24